Trial Profile

A Phase I/II study of clofarabine in combination with cytarabine and liposomal daunorubicin in children with relapsed/refractory pediatric AML

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 12 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Clofarabine (Primary) ; Cytarabine; Cytarabine; Daunorubicin liposomal
Indications Acute myeloid leukaemia
Focus Adverse reactions
Acronyms CLARA-DNX

Most Recent Events

23 Dec 2015 Status changed from recruiting to completed, as reported by Netherlands Trial Register.
29 Jul 2014 In phase 1b, 2 patients had dose-limiting toxicities at dose level 3 which required suspension of dose-escalation. Hence, the protocol was amended requiring screening of the patients with computer tomography and serum-galactomannan prior to enrollment.
10 Dec 2013 Interim results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com